SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Rule 13d-101)
Information
to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments
Thereto Filed
Pursuant to § 240.13d-2(a)
Under the Securities
Exchange Act of 1934
OASMIA PHARMACEUTICAL AB
(Name of Issuer)
COMMON STOCK, PAR VALUE SEK 0.1 PER SHARE
(Title of Class of Securities)
SE0000722365
(ISIN Number)
Gregory Sichenzia, Esq.
Henry Nisser, Esq.
Sichenzia Ross Ference Kesner LLP
61 Broadway, 32
nd
Floor,
New York, NY 10006
Tel: (212) 930-9700
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 21, 2015
(Date of Event Which Requires Filing of
This Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
¨
.
Note
. Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to
whom copies are to be sent.
______________
1 The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
a prior cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however,
see
the
Notes
).
ISIN No. SE0000722365
|
13D
|
Page 2 of 5 Pages
|
1
|
NAME OF REPORTING PERSONS
Alceco International S.A.
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
|
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS) WC
|
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e)
|
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
|
|
NUMBER OF
SHARES
|
7
|
SOLE VOTING POWER
|
0
|
BENEFICIALLY
OWNED
BY
|
8
|
SHARED VOTING POWER
|
25,392,018
|
EACH
REPORTING
PERSON
|
9
|
SOLE DISPOSITIVE POWER
|
0
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
|
25,392,018
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
25,392,018
|
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
|
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
21.33% (1)
|
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
CO
|
|
(1)
|
Percentage of beneficial ownership is calculated under
applicable SEC regulations based upon 119,039,310 Shares outstanding as of January 31, 2017.
|
ISIN No. SE0000722365
|
13D
|
Page 3 of 5 Pages
|
Item 1. Security and Issuer.
This Statement on Schedule 13D (this “
Statement
”)
relates to the ordinary shares, SEK 0.1 par value (the “
Shares
”) of Oasmia Pharmaceutical AB (the “
Issuer
”).
The principal executive offices of the Issuer are located at Vallongatan 1, 752 28 Uppsala, Sweden.
Item 2. Identity and Background.
This statement is filed on behalf of (i)
Alceco International, S.A., a Luxembourg corporation (“
Alceco
”) with a business address at 18-20 rue Gabriel
Lippmann, L-5365 Munsbach, Luxembourg, (ii) Julian Aleksov, a citizen of Sweden (“
Mr. Aleksov
”), and (3iii)
Bo Cederstrand, a citizen of Sweden (“
Mr. Cederstrand
”). Such parties are referred to herein individually as
a “
Reporting Person
” and collectively as the “
Reporting Persons
.”
Messrs. Aleksov and Cederstrand are the
two directors of Alceco. The Reporting Persons are making this single, joint filing because they may be deemed to constitute a
“group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. Each
Reporting Person disclaims beneficial ownership of the shares of Common Stock owned by any person other than such Reporting Person
except to the extent of any pecuniary interest therein.
The principal business address of Alceco
is 18-20 rue Gabriel Lippmann, L-5365 Munsbach, Luxembourg. The principal business address of Messrs. Aleksov and Cederstrand is
c/o the Issuer at Vallongatan 1, 752 28 Uppsala, Sweden.
None of the Reporting Persons has, during
the past five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). None
of the Reporting Persons has, during the past five years, been a party to a civil proceeding of a judicial or administrative body
of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with
respect to such laws.
Item 3. Source and Amount of Funds or
Other Consideration.
The Shares were acquired by Alceco using
its working capital.
Alceco has been a beneficial owner since
the inception of the Company on April 15, 1988 and remains the beneficial owner of Shares in excess of five percent (5%) of the
issued and outstanding Shares. Historically, several transactions have been made by Alceco.
Item 4. Purpose of Transaction.
Alceco acquired the Shares for investment
purposes as well as to finance the Company’s operations.
Item 5. Interest in Securities of the Issuer.
The following table sets forth the aggregate
number and percentage of shares of the Company’s common stock beneficially owned by the reporting person herein:
Reporting Person
|
Shares Beneficially Owned
(1)
|
Percent
(2)
|
|
25,392,018
|
21.33%
|
(1) Messrs. Aleksov and Cederstrand are
the control persons of Alceco.
(2) Percentage of beneficial ownership
is calculated under applicable SEC regulations based upon 119,039,310 Shares issued and outstanding as of January 31, 2017.
ISIN No. SE0000722365
|
13D
|
Page 4 of 5 Pages
|
Item 6. Contracts, Arrangements, Understandings
or Relationships with Respect to Securities of the Issuer.
By virtue of the relationship among the
Reporting Persons, the Reporting Persons may be deemed to be a “group” under the Federal securities laws. Other than
the relationship between the Reporting Persons as described above under Items 2-5 above, there are no contracts, arrangements,
understandings or relationships (legal or otherwise) between any of the Reporting Persons and any other person with respect to
any securities of the Issuer, except that (i) Mr. Aleksov is the partner of Mr. Cederstrand’s daughter and the father of
his two grandchildren, and (ii) Alceco has extended a credit facility of SEK 40 million to the Issuer, which as of the date hereof
has not been drawn upon.
Item 7. Material to be Filed as Exhibits.
Joint Filing Agreement, dated as of February
13, 2017, by and among Alceco, Mr. Aleksov and Mr. Cederstrand (filed herewith).
ISIN No. SE0000722365
|
13D
|
Page 5 of 5 Pages
|
SIGNATURES
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.
February 13, 2017
|
ALCECO INTERNATIONAL, S.A.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Julian Aleksov
|
|
|
Name:
|
Julian Aleksov
|
|
|
Title:
|
Director
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Julian Aleksov
|
|
|
Julian Aleksov
|
|
|
|
|
|
|
|
|
|
|
/s/ Bo Cederstrand
|
|
|
Bo Cederstrand
|
|
Exhibit A
JOINT FILING AGREEMENT
This Joint Filing
Agreement is filed as an exhibit to Schedule 13D being filed by Alceco International, S.A., Julian Aleksov and Bo Cederstrand.
in compliance with Rule 13d-1(k) of the Securities and Exchange Commission, which requires an agreement in writing indicating that
the Schedule 13D to which this Agreement is attached is filed on behalf of the below-named entities, that they are each responsible
for the timely filing of the Schedule 13D and any amendments thereto and for the completeness and accuracy of the information concerning
such persons contained therein.
This Joint Filing
Agreement may be executed in counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts
together shall constitute one agreement.
In evidence thereof,
the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of February 13, 2017.
|
ALCECO INTERNATIONAL, S.A.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Julian Aleksov
|
|
|
Name:
|
Julian Aleksov
|
|
|
Title:
|
Director
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Julian Aleksov
|
|
|
|
|
|
|
|
|
|
|
/s/ Bo Cederstrand
|
|
|
Bo Cederstrand
|
|
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Sep 2023 to Sep 2024